Core Laboratories (NYSE:CLB – Get Free Report) is anticipated to post its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to post earnings of $0.08 per share and revenue of $126.2580 million for the quarter. Core Laboratories has set its Q2 2026 guidance at 0.060-0.120 EPS. Individuals can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.
Core Laboratories (NYSE:CLB – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The oil and gas company reported $0.06 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.06. The firm had revenue of $121.80 million for the quarter, compared to the consensus estimate of $122.99 million. Core Laboratories had a net margin of 5.94% and a return on equity of 11.52%. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.14 EPS. On average, analysts expect Core Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Core Laboratories Stock Up 2.6%
Shares of NYSE CLB opened at $11.48 on Wednesday. The company’s 50 day moving average price is $12.44 and its 200-day moving average price is $15.60. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.50 and a current ratio of 2.05. Core Laboratories has a 52-week low of $9.72 and a 52-week high of $20.36. The company has a market capitalization of $529.46 million, a P/E ratio of 17.67, a price-to-earnings-growth ratio of 2.70 and a beta of 1.00.
Core Laboratories Announces Dividend
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on CLB shares. Wall Street Zen lowered shares of Core Laboratories from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Weiss Ratings downgraded Core Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.
View Our Latest Stock Analysis on Core Laboratories
Hedge Funds Weigh In On Core Laboratories
Institutional investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd acquired a new stake in shares of Core Laboratories during the 4th quarter worth approximately $34,000. Quarry LP increased its stake in shares of Core Laboratories by 118.1% in the 3rd quarter. Quarry LP now owns 2,953 shares of the oil and gas company’s stock valued at $36,000 after acquiring an additional 1,599 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Core Laboratories by 400.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,333 shares of the oil and gas company’s stock valued at $84,000 after acquiring an additional 5,869 shares during the period. Vestcor Inc acquired a new position in shares of Core Laboratories during the 3rd quarter valued at $101,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in Core Laboratories during the third quarter worth $132,000. 97.81% of the stock is owned by institutional investors and hedge funds.
Core Laboratories Company Profile
Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.
The company’s portfolio spans two primary service lines: reservoir description and production enhancement.
Featured Articles
- Five stocks we like better than Core Laboratories
- Confidence Is Back, But Earnings Show the Consumer Is Being Picky
- AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off
- 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative?
- 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
